The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of an oral study drug for weight management and type 2 diabetes (T2D). This study will be looking at the effects of the study drug when combined with 2 different medications.
Obesity and T2D are chronic conditions that often co-occur and can increase the risk of developing other illnesses and diseases. Both are growing concerns around the world, and by 2030 it is projected that over a billion people worldwide will be considered obese.
Despite the availability of treatments, approximately half of people diagnosed with T2D are not at their blood sugar goal, while most people with obesity do not receive any treatment at all. Diet and lifestyle are also often not effective for long-term weight and blood-sugar management for many patients. Pfizer is committed to developing breakthrough treatments for people with these conditions.
Read more about how you can help as a healthy volunteer below.
Who may participate
As a healthy clinical trial participant, you are at the center of drug discoveries that could help patients around the world.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Able to come and stay at our facility in New Haven, CT for the duration of participation in the study*
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
All sexes
Referral bonus
Up to $175
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 13 consecutive overnights. Starting the morning after admission, you will receive doses of the study drug and two other medications in 3 separate stages, called periods, as described below:
- A single dose of the study drug by itself
- A single dose of the study drug combined with another medication
- Daily doses of a third medication for 6 days, with the study drug also given on the 4th day
All doses are provided as tablets, capsules, or liquids to swallow and will be given after breakfast. There are about 3 days between the start of each period.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
Required overnight stays
13 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 40 days
Compensation
Up to $5,950 upon completion of the study
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.